H. Dineaslan Et Al. , "The First Report Related to First-Line Therapy with Anti-CD30 Combined Modified Chemotherapy in a Child with Hodgkin Disease Underlying Combined Immunodeficiency," PEDIATRIC BLOOD & CANCER , vol.65, 2018
Dineaslan, H. Et Al. 2018. The First Report Related to First-Line Therapy with Anti-CD30 Combined Modified Chemotherapy in a Child with Hodgkin Disease Underlying Combined Immunodeficiency. PEDIATRIC BLOOD & CANCER , vol.65 .
Dineaslan, H., ÜNAL, E., TAÇYILDIZ, N., Tanyildiz, G., KULOĞLU, Z., KAYGUSUZ, G., ... Cakmak, M.(2018). The First Report Related to First-Line Therapy with Anti-CD30 Combined Modified Chemotherapy in a Child with Hodgkin Disease Underlying Combined Immunodeficiency. PEDIATRIC BLOOD & CANCER , vol.65.
Dineaslan, H. Et Al. "The First Report Related to First-Line Therapy with Anti-CD30 Combined Modified Chemotherapy in a Child with Hodgkin Disease Underlying Combined Immunodeficiency," PEDIATRIC BLOOD & CANCER , vol.65, 2018
Dineaslan, H. Et Al. "The First Report Related to First-Line Therapy with Anti-CD30 Combined Modified Chemotherapy in a Child with Hodgkin Disease Underlying Combined Immunodeficiency." PEDIATRIC BLOOD & CANCER , vol.65, 2018
Dineaslan, H. Et Al. (2018) . "The First Report Related to First-Line Therapy with Anti-CD30 Combined Modified Chemotherapy in a Child with Hodgkin Disease Underlying Combined Immunodeficiency." PEDIATRIC BLOOD & CANCER , vol.65.
@article{article, author={H. Dineaslan Et Al. }, title={The First Report Related to First-Line Therapy with Anti-CD30 Combined Modified Chemotherapy in a Child with Hodgkin Disease Underlying Combined Immunodeficiency}, journal={PEDIATRIC BLOOD & CANCER}, year=2018}